It has been predicted that costs for cardiovascular disease will increase to more than $1 trillion dollars annually in the US by 2030. If statins are effective in preventing heart disease, why are costs still rising?
The explosion of data regarding residual risk and contributions from LDL-P predicts an exciting future. Right now, treatment regimens are in flux awaiting further details on LDL-P interventions and a host of new drugs.
Two studies have demonstrated novel research directions for LDL-C and LDL-P. The first revealed that when LDL-C and LDL-P are concordant (that is either both high, normal, or low), either can serve as a good measure of CV risk. However, when they are discordant, cardiovascular events increase.
Reducing hyperglycemia in older patients with chronic kidney disease may be best accomplished using incretin-based agents.
PCSK-9 inhibition in patients with recalcitrant hypercholesterolemia has reaped reductions in LDL-C of up to 85% after the first week of therapy.
In patients deemed statin-intolerant, lifestyle changes and alternative classes of drugs should be pursued to lower LDL-C.
Despite best efforts with lifestyle modification and adherence to metformin and glimepiride therapy, this man’s A1C continues to rise. What next?
Achieving sustained reductions of hyperlipidemia and blood pressure in a patient with diabetes is not impossible, but it's a challenge. A new study comparing two health systems shows which factors increase the odds of success.
A genetic analysis questions the benefits of raising HDL-C levels to reduce the risk of MI and of the value of HDL-C as a surrogate marker of risk.
High HDL levels track with low MI risk. But a Harvard medical geneticist tells why you may not be able to reduce that risk by intervening to raise them.